Core Scientific Inctx
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
CORZ$12.72+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets (Unaudited)
Consolidated Balance Sheets
(in thousands, except par value)
| March 31,2024 | December 31,2023 | |
|---|---|---|
| Assets · (Unaudited) | ||
| Current Assets: | ||
| Cash and cash equivalents | $98,125 | $50,409 |
| Restricted cash | 16,151 | 19,300 |
| Accounts receivable | 1,107 | 1,001 |
| Digital assets | — | 2,284 |
| Prepaid expenses and other current assets | 27,937 | 24,022 |
| Total Current Assets | 143,320 | 97,016 |
| Property, plant and equipment, net | 575,969 | 585,431 |
| Operating lease right-of-use assets | 77,766 | 7,844 |
| Intangible assets, net | 2,136 | 2,247 |
| Other noncurrent assets | 14,777 | 19,618 |
| Total Assets | $813,968 | $712,156 |
| Liabilities and Stockholders’ Deficit | ||
| Current Liabilities: | ||
| Accounts payable | $16,165 | $154,751 |
| Accrued expenses and other current liabilities | 68,221 | 179,636 |
| Deferred revenue | 9,250 | 9,830 |
| Operating lease liabilities, current portion | 2,619 | 77 |
| Finance lease liabilities, current portion | 3,018 | 19,771 |
| Notes payable, current portion | 23,333 | 124,358 |
| Contingent value rights, current portion | 15,539 | — |
| Total Current Liabilities | 138,145 | 488,423 |
| Operating lease liabilities, net of current portion | 69,022 | 1,512 |
| Finance lease liabilities, net of current portion | 1,170 | 35,745 |
| Convertible and other notes payable, net of current portion | 556,573 | 684,082 |
| Contingent value rights, net of current portion | 29,062 | — |
| Warrant liabilities | 327,465 | — |
| Other noncurrent liabilities | 11,040 | — |
| Total liabilities not subject to compromise | 1,132,477 | 1,209,762 |
| Liabilities subject to compromise | — | 99,335 |
| Total Liabilities | 1,132,477 | 1,309,097 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ Deficit: | ||
| Preferred stock; $0.00001 par value; 2,000,000 shares authorized; none issued and outstanding | — | — |
| Common stock; $0.00001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; 182,237 and 386,883 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 2 | 36 |
| Additional paid-in capital | 1,891,011 | 1,823,260 |
| Accumulated deficit | (2,209,522) | (2,420,237) |
| Total Stockholders’ Deficit | (318,509) | (596,941) |
| Total Liabilities and Stockholders’ Deficit | $813,968 | $712,156 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.